Dr. Chaturvedi's lab focuses on the following ares:

Genomics and Devices – We are interested in the applications of the whole-genome sequencing (WGS) to understand the emergence and dissemination of bacterial and fungal pathogens. We have developed and validated WGS methods and applied deep sequencing to understand infectious disease dynamics. We are passionate about introduction of new diagnostic tests to address the challenges of emerging and re-emerging pathogenic fungi and aim to promote the adaptation of new technologies by the clinical microbiology laboratories.

Antifungals Drugs – We have a sustained record of productivity in innovation of laboratory testing of antifungal drugs. With support from major pharmaceutical companies, we developed several rapid and sensitive methods for susceptibility testing of antifungals alone and in combination. We have also participated and lead numerous multi-laboratory studies to standardize antifungal susceptibility testing methods for the clinical laboratories.

Epidemiology of Microbial Diseases – We have made several major contributions to molecular epidemiology of fungal and bacterial pathogens in the United States. Many collaborative publications described new laboratory tools, undocumented clinical conditions, and occurrence of pathogens outside of known endemic areas. We lead rapid outbreak investigations, characterizations of unknown pathogens, defined pathogen virulence, and provided a bridge between basic and translational science.

Previous professional positions: New York State Department of Health, California Department of Public Health, and Yale University School of Medicine

Education

• Ph.D., Medical Microbiology, Delhi University
• Postdoc., Infectious Diseases, University of Cincinnati
• Postdoc., Infectious Diseases, Universidad Complutense de Madrid

Research

Dr. Chaturvedi's laboratory focuses on applying whole-genome sequencing (WGS) to study the emergence and spread of bacterial and fungal pathogens, developing and validating WGS methods to enhance understanding of infectious disease dynamics and advance diagnostic tests for pathogenic fungi. They are committed to integrating new technologies into clinical microbiology. In antifungal drug research, they have pioneered rapid, sensitive susceptibility testing methods with support from pharmaceutical companies and have led efforts to standardize these methods across multiple laboratories. Their work in molecular epidemiology has significantly contributed to understanding fungal and bacterial pathogens in the U.S., including rapid outbreak investigations, characterization of unknown pathogens, and defining pathogen virulence, bridging the gap between basic and translational science.

Publications

View All Publications

Memberships and Affiliations

• Editor-in-Chief, Mycopathologia